These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 7519209)

  • 1. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
    Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
    Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytotoxic effector cells: definition and analysis of activity.
    Ortaldo JR
    Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
    Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns.
    Doherty DG; Norris S; Madrigal-Estebas L; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
    J Immunol; 1999 Aug; 163(4):2314-21. PubMed ID: 10438977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice.
    Wongkajornsilp A; Somchitprasert T; Butraporn R; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Maneechotesuwan K; Hongeng S
    Cancer Invest; 2009 Feb; 27(2):140-8. PubMed ID: 19235585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
    Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of natural killer cells for clinical applications.
    Klingemann HG; Martinson J
    Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2.
    Satoh M; Seki S; Hashimoto W; Ogasawara K; Kobayashi T; Kumagai K; Matsuno S; Takeda K
    J Immunol; 1996 Nov; 157(9):3886-92. PubMed ID: 8892619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
    Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
    Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
    Wang J; He M; Shi W; Sha H; Feng J; Wang S; Wang Y
    Cancer Invest; 2009 Mar; 27(3):244-50. PubMed ID: 19194830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.